
Optic automates drug discovery and development by using AI to find, evaluate, and prioritize drug candidates for biopharma teams. The platform combines generative AI for molecule design with ligand-based and structure-based models, large language models, and agentic AI agents to triage scientific and business tasks such as in-licensing, diligence, and commercialization. Optic operates as a SaaS AI-native pharma platform and runs multiple internal preclinical programs while partnering with biotech companies and universities. Core technologies include generative AI, agentic AI, ligand- and structure-based molecular models, LLMs, and NVIDIA T4 GPU acceleration. The product targets biopharma and biotech customers seeking faster molecule discovery and end-to-end AI-driven development workflows.

Optic automates drug discovery and development by using AI to find, evaluate, and prioritize drug candidates for biopharma teams. The platform combines generative AI for molecule design with ligand-based and structure-based models, large language models, and agentic AI agents to triage scientific and business tasks such as in-licensing, diligence, and commercialization. Optic operates as a SaaS AI-native pharma platform and runs multiple internal preclinical programs while partnering with biotech companies and universities. Core technologies include generative AI, agentic AI, ligand- and structure-based molecular models, LLMs, and NVIDIA T4 GPU acceleration. The product targets biopharma and biotech customers seeking faster molecule discovery and end-to-end AI-driven development workflows.
Company: Optic
Headquarters: San Francisco, California, United States
Founded: 2021
Industry: Biotechnology
Latest disclosed funding: Seed (Jul 20, 2022), total reported $22,000,000
Drug discovery and development, hit identification to preclinical advancement
2021
Biotechnology
22000000
“Includes institutional and crypto investors such as Kleiner Perkins, Pantera Capital, Polygon, BBQ Capital, CoinDCX, Neon DAO, Flamingo DAO”